You are here
Immunext, Inc.
UEI: SBSALV1MKHA3
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases
Amount: $2,959,557.00Glucocorticoids (GC) are a class of drugs with overwhelming anti-inflammatory activities. However, dose limiting toxicities (DLT) caused by systemic GC exposure prevent GC from being a true panacea in ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
Amount: $299,502.00ImmuNext has defined an anti MCTmonoclonal antibodymAbthat will be developed for the treatment of human autoimmune diseaseThe membrane monocarboxylate nutrient transporter SLCAMCTis a multi pass trans ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
Amount: $2,987,732.00ImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
Amount: $299,938.00ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibody mAb that we aim to bring to the clinic for the treatment of human autoimmune disease VISTA is a member of the hi ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
Amount: $2,988,407.00ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly s ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Safe and effective anti CD antibodies for therapeutic intervention
Amount: $1,824,382.00Abstract CD CD L is a key target for immunomodulation due to its central role in controlling the activation of the immune system This well studied immune switch has been the focus of extensi ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
Amount: $1,949,257.00DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ sy ...
STTRPhase II2014Department of Health and Human Services National Institutes of Health -
Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention
Amount: $290,914.00DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 t ...
STTRPhase I2013Department of Health and Human Services National Institutes of Health -
Safe and effective anti CD154 antibodies for therapeutic intervention
Amount: $2,960,698.00DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
Amount: $600,000.00DESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lea ...
STTRPhase I2012Department of Health and Human Services National Institutes of Health